靶向共有新抗原的肿瘤疫苗和细胞治疗新进展
Progress in tumor vaccines and cell therapies targeting shared neoantigens
曹鑫 1刘芹 1刘宝瑞1
作者信息
- 1. 南京大学医学院附属鼓楼医院肿瘤中心,江苏南京 210008
- 折叠
摘要
共有新抗原是肿瘤患者中共同呈现的免疫原性表位,通常由肿瘤驱动基因的热点突变产生,仅在肿瘤组织中表达,作为肿瘤特异性抗原刺激机体产生免疫反应.共有新抗原因其"现货型"、通用性、高特异性、强免疫原性等优势受到研究人员的青睐.本文阐述了共有新抗原的来源、特点及常见的共有新抗原,着重阐述了靶向共有新抗原疫苗治疗和细胞治疗的研究进展,列举相关的临床试验,并简述了提高共有新抗原疫苗与细胞治疗的策略.
Abstract
Shared neoantigens are immunogenic epitopes that are commonly found in tumor patients and are usually genera-ted by hotspot mutations in tumor driver genes.They are expressed only in tumor tissues and act as tumor-specific anti-gens to stimulate an immune response.Shared neoantigens are favored by researchers because of their"off-the-shelf"avail-ability,universality,highly specificity,and strong immunogenicity.This review describes in detail the sources,characteris-tics and common shared neoantigens,focusing on the research progress of novel therapeutic methods such as vaccine thera-py and cell therapy targeting shared neoantigens.Also,this article lists the relevant clinical trials,and briefly describes the strategies to improve the vaccine and cell therapy against shared neoantigens.
关键词
共有新抗原/肿瘤治疗性疫苗/热点突变/过继细胞治疗Key words
shared neoantigens/therapeutic tumor vaccines/hotspot mutations/adoptive cell therapy引用本文复制引用
出版年
2024
NETL
NSTL
万方数据